Elisa Tonoli

Dr. Elisa Tonoli

Nottingham Trent University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in Micromachines
Verified
Journal Article
Open access
PDF file
MSMaria Pia Savoca
Maria Pia Savoca
Elisa TonoliElisa Tonoli
Elisa Tonoli
AAAdeola G. Atobatele
Adeola G. Atobatele
Elisabetta A.M. VerderioElisabetta A.M. Verderio
Elisabetta A.M. Verderio
The biocatalytic activity of transglutaminases (TGs) leads to the synthesis of new covalent isopeptide bonds (crosslinks) between peptide-bound glutamine and lysine residues, but also the transamidation of primary amines to glutamine residues, which ultimately can result into protein polymerisation. Operating with a cysteine/histidine/aspartic acid (Cys/His/Asp) catalytic triad, TGs induce the post-translational modification of proteins at both physiological and pathological conditions (e.g., accumulation of matrices in tissue fibrosis). Because of the disparate biotechnological applications, this large family of protein-remodelling enzymes have stimulated an escalation of interest. In the past 50 years, both mammalian and microbial TGs polymerising activity has been exploited in the food industry for the improvement of aliments’ quality, texture, and nutritive value, other than to enhance the food appearance and increased marketability. At the same time, the ability of TGs to crosslink extracellular matrix proteins, like collagen, as well as synthetic biopolymers, has led to multiple applications in biomedicine, such as the production of biocompatible scaffolds and hydrogels for tissue engineering and drug delivery, or DNA-protein bio-conjugation and antibody functionalisation. Here, we summarise the most recent advances in the field, focusing on the utilisation of TGs-mediated protein multimerisation in biotechnological and bioengineering applications.

5 September 2019 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
YWYuncheng Wu
Yuncheng Wu
Tao LyuTao Lyu
Tao Lyu
BYBin Yue
Bin Yue
Elisa TonoliElisa Tonoli
Elisa Tonoli
EVElisabetta A. M. Verderio
Elisabetta A. M. Verderio
Gang PanGang Pan
Gang Pan

19 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Giuseppe Di FedeGiuseppe Di Fede
Giuseppe Di Fede
MCMarcella Catania
Marcella Catania
EMEmanuela Maderna
Emanuela Maderna
RGRoberta Ghidoni
Roberta Ghidoni
LBLUISA BENUSSI
LUISA BENUSSI
FTFabrizio Tagliavini
Fabrizio Tagliavini
Protein misfolding and aggregation is a central feature of several neurodegenerative disorders including Alzheimer’s disease (AD), in which assemblies of amyloid β (Aβ) peptides accumulate in the brain in the form of parenchymal and/or vascular amyloid. A widely accepted concept is that AD is characterized by distinct clinical and neuropathological phenotypes. Recent studies revealed that Aβ assemblies might have structural differences among AD brains and that such pleomorphic assemblies can correlate with distinct disease phenotypes. We found that in both sporadic and inherited forms of AD, amyloid aggregates differ in the biochemical composition of Aβ species. These differences affect the physicochemical properties of Aβ assemblies including aggregation kinetics, resistance to degradation by proteases and seeding ability. Aβ-amyloidosis can be induced and propagated in animal models by inoculation of brain extracts containing aggregated Aβ. We found that brain homogenates from AD patients with different molecular profiles of Aβ are able to induce distinct patterns of Aβ-amyloidosis when injected into mice. Overall these data suggest that the assembly of mixtures of Aβ peptides into different Aβ seeds leads to the formation of distinct subtypes of amyloid having distinctive physicochemical and biological properties which result in the generation of distinct AD molecular subgroups.

30 January 2018 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
GFGiulia Furini
Giulia Furini
NSNina Schroeder
Nina Schroeder
LHLinghong Huang
Linghong Huang
DBDavid Boocock
David Boocock
ASAlessandra Scarpellini
Alessandra Scarpellini
Elisabetta A.M. VerderioElisabetta A.M. Verderio
Elisabetta A.M. Verderio
Increased export of transglutaminase-2 (TG2) by tubular epithelial cells (TECs) into the surrounding interstitium modifies the extracellular homeostatic balance, leading to fibrotic membrane expansion. Although silencing of extracellular TG2 ameliorates progressive kidney scarring in animal models of CKD, the pathway through which TG2 is secreted from TECs and contributes to disease progression has not been elucidated. In this study, we developed a global proteomic approach to identify binding partners of TG2 responsible for TG2 externalization in kidneys subjected to unilateral ureteric obstruction (UUO) using TG2 knockout kidneys as negative controls. We report a robust and unbiased analysis of the membrane interactome of TG2 in fibrotic kidneys relative to the entire proteome after UUO, detected by SWATH mass spectrometry. The data have been deposited to the ProteomeXchange with identifier PXD008173. Clusters of exosomal proteins in the TG2 interactome supported the hypothesis that TG2 is secreted by extracellular membrane vesicles during fibrosis progression. In established TEC lines, we found TG2 in vesicles of both endosomal (exosomes) and plasma membrane origin (microvesicles/ectosomes), and TGF-β1 stimulated TG2 secretion. Knockout of syndecan-4 (SDC4) greatly impaired TG2 exosomal secretion. TG2 coprecipitated with SDC4 from exosome lysate but not ectosome lysate.Ex vivo, EGFP-tagged TG2 accumulated in globular elements (blebs) protruding/retracting from the plasma membrane of primary cortical TECs, and SDC4 knockout impaired bleb formation, affecting TG2 release. Through this combinedin vivoandin vitroapproach, we have dissected the pathway through which TG2 is secreted from TECs in CKD.

1 April 2016 in Neurobiology of Aging
Verified
Journal Article
Closed access
LBLUISA BENUSSI
LUISA BENUSSI
MCMiriam Ciani
Miriam Ciani
Elisa TonoliElisa Tonoli
Elisa Tonoli
MMMichela Morbin
Michela Morbin
LPLuisa Palamara
Luisa Palamara
RGRoberta Ghidoni
Roberta Ghidoni

10 December 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
LBLuisa Benussi
Luisa Benussi
GRGiacomina Rossi
Giacomina Rossi
MGMichela Glionna
Michela Glionna
Elisa TonoliElisa Tonoli
Elisa Tonoli
EPElena Piccoli
Elena Piccoli
RGRoberta Ghidoni
Roberta Ghidoni
Expansion of a hexanucleotide repeat in the C9ORF72 gene has been identified as the most common pathogenic mutation in families with autosomal dominant frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis. Herein we investigated frequency and penetrance of the C9ORF72 hexanucleotide repeat pathological expansion in a large cohort of familial and sporadic FTLD and related disorders (FTLD and related disorders, n = 388; Controls, n = 201). Moreover, we weighed the impact of C9ORF72 genotype on clinical phenotype taking into account the hexanucleotide repeat units number as a possible disease modifier. In our cohort, the C9ORF72 pathological expansion: i) showed a prevalence of 7.5%; ii) showed a full penetrance by the age of 80; iii) was rarely found in sporadic patients; iv) was solely associated with FTLD; v) was mainly associated with bvFTD clinical subtype; and vi) was associated with earlier age of onset in the youngest generation compared with the previous generation within a pedigree. Interestingly, intermediate C9ORF72 expansion had a risk effect in familial/sporadic FTLD. Eventually, the C9ORF72 repeat units number influenced the disease phenotype in terms of age of onset and associated clinical subtype. Genome-wide studies in well characterized clinical cohorts will be essential in order to decipher pathways of disease expression in C9ORF72-associated neurodegeneration.